Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 2, 2010, Pages 267-274

  Jin, Cheng ^a   Li, Haimin ^a   He, Yong ^a   He, Min ^b   Bai, Ling ^c   Cao, Yunxin ^d   Song, Wenjie ^a   Dou, Kefeng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Surgery   (China)

^c Xi'an Gaoxin Hospital   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Combination chemotherapy; Doxorubicin; Hepatocellular carcinoma; Paclitaxel

Indexed keywords

DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HEPG2; CELL STRUCTURE; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; FLOW CYTOMETRY; G2 PHASE; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74049119820     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0658-5     Document Type: Article

References (28)

1. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261.
2. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R (1993) Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 5:141-147.
3. Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S et al (2006) Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as Wrstline treatment in patients with metastatic breast cancer. Am J Clin Oncol 29:267-275.
4. Carr BI, Iwatsuki S, Baron R, Jain A, Selby R, Madariaga J et al (1993) Intrahepatic arterial cisplatinum and doxorubicin with or without lipiodol for advanced hepatocellular carcinoma (HCC): a prospective randomized study. Proc Annu Meet Am Soc Clin Oncol 12:A668.
5. Geng CX, Zeng ZC, Wang JY (2003) Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 9:696-700.
6. Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK et al (2008) A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline. Cancer Chemother Pharmacol 61:847-853.
7. Iesalnieks I, Tange S, Scherer MN, Graeb C, Frank E, Jauch KW et al (2002) Paclitaxel promotes liver graft survival in rats and inhibits hepatocellular carcinoma growth in vitro and is a potentially useful drug for transplant patients with liver cancer. Transplant Proc 34:2316-2317.
8. Johnson PJ (2002) Hepatocellular carcinoma: is current therapy really altering outcome? Gut 51:459-462.
9. Johnson PJ (2003) Are there indications for chemotherapy in hepatocellular carcinoma? Surg Oncol Clin N Am 12:127-134.
10. Lau WY, Ho S, Leung WT, Chan M, Ho R, Johnson PJ et al (1998) Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intra-arterial infusion of yttrium-90 microspheres. Int J Radiat Oncol Biol Phys 40:583-592.
11. Leung WT, Johnson PJ (2001) Systemic therapy for hepatocellular carcinoma. Semin Oncol 28:514-529.
12. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917.
13. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M et al (1993) Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 217:375-384.
14. Nerenstone SR, Ihde DC, Friedman MA (1988) Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15:1-31.
15. Okano J, Nagahara T, Matsumoto K, Murawaki Y (2007) The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis. Oncol Rep 17:1195-1200.
16. Palmer DH, Hussain SA, Johnson PJ (2004) Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 13:1555-1568.
17. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
18. Patt YZ, Charnsangavej C, YoVe B, Smith R, Lawrence D, Chuang V et al (1994) Hepatic arterial infusion of Xoxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12:1204-1211.
19. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P et al (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181-184.
20. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ et al (2008) Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:1980-1986.
21. Shi P, Wang MM, Jiang LY, Liu HT, Sun JZ (2008) Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression. Chin Med J (Engl) 121:1975-1979.
22. Strumberg D, Erhard J, Harstrick A, Klaassen U, Müller C, Eberhardt W et al (1998) Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer 34:1290-1292.
23. Tanaka H, Kubo S, Tsukamoto T, Shuto T, Takemura S, Yamamoto T et al (2005) Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 37:1254-1256.
24. Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339-346.
25. World Health Organization (2008) Motality database. WHO statistical information system. Available at: http://www.who.int/whosis/. Accessed July 2008.
26. Yamamoto S, Sato Y, Takeishi T, Hirano K, Kobayashi T, Watanabe T et al (2005) Successful surgical treatment for hepatocellular carcinoma and concomitant risky esophageal varices. Hepatogastroenterology 52:1083-1086.
27. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY et al (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538.
28. Zhang ZL, Liu ZS, Sun Q (2005) Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice. Chin Med J (Engl) 118:1688-1694.